Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Novartis Pharmaceuticals
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Patients were included in the study if they met all of the following criteria:
Patient was prescribed ofatumumab within the UK approved marketing authorization
Patient initiated ofatumumab via participating MS clinic with or without KC PSP
Patients initiated ofatumumab during the index identification window
Authorized to collect study data:
1. Patient was alive at start of data collection and patient consented prior to start of their data collection or,
2. Patient was deceased at start of data collection and a member of the patient's direct care team had a pre-existing right to access patient medical record
Specifically for adherence analyses: Patients were required to have a minimum of 6 months of follow-up post index date available to make this assessment
Specifically for clinical effectiveness analyses: Patients were required to have a minimum of 6 months look-back pre-index date and minimum 6 months follow-up post index date available to make this assessment.
You may not be if
Patients were excluded from the study if they met the following criteria:
Patient prescribed ofatumumab outside the approved marketing authorization (i.e., under off-label prescribing) at any point within the patients record
Clareo Health | A Study of Multiple Sclerosis Routine Clinical Practice: Impact on Adherence and Clinical Outcomes of Ofatumumab Treated Patients
